Promising Prospects Expected in 2026 for GE HealthCare Technologies (GEHC)

GE HealthCare Technologies (NASDAQ:GEHC) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds.

On January 9, David Roman from Goldman Sachs reiterated his Buy rating for GE HealthCare Technologies (NASDAQ:GEHC). The analyst also raised his price target from $86 to $98, implying nearly 24% upside for investors.

On January 5, Vijay Kumar of Evercore ISI also expressed a bullish stance on GE HealthCare Technologies (NASDAQ:GEHC). He maintained an Outperform rating on the stock and anticipated nearly 20% upside from the prevailing level. This upside is based on Kumar’s upward revision of the price target from $92 to $95.

Kumar noted that 2026 is set to offer interesting prospects given a visible recovery across end markets, along with sector rotation strategies. For the medical technology space, he expects strong capital expenditure trends next year, which will be supported by recovery indicators in China.

GE HealthCare Technologies (NASDAQ:GEHC) operates within pharmaceutical diagnostics and medical technology spaces. With a focus on precision care, it develops and markets products along with additional services that are used in diagnosis, treatment and monitoring of patients. It is structured in four segments: Advanced Visualization Solutions (AVS), Imaging, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).

While we acknowledge the potential of GEHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.